Wednesday, 02 April 2014 10:03

Anticoagulation news items. Week commencing 24th March 2014

Five-Year Survival in Patients with ST-Segment Elevation Myocardial Infarction According to Modalities of Reperfusion Therapy: The French Registry on Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) 2005 Cohort

 

Circulation

 

This analysis of registry data reports 5-year survival following STEMI of 88% for patients receiving fibrinolysis, 83% for PCI and 59% for no reperfusion. The authors suggest a pharmaco-invasive strategy constitutes a valid alternative to PCI on a nationwide scale.

 

 

Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial

 

European Heart Journal

 

This analysis of data from 779 pts experiencing major bleeding during ROCKET AF found administration of fresh frozen plasma and prothrombin complex concentrates was less frequent in the rivaroxaban arm. Use of transfused packed RBC and outcomes were however similar to warfarin.

 

 

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service.
Further details on this service can be found at: http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services